DEMANT Demant A/S

Demant A/S: Capital reduction as well as total number of voting rights and capital

Demant A/S: Capital reduction as well as total number of voting rights and capital

Company announcement no 2020-0620 April 2020

Completion of capital reduction in Demant A/S

As stated in company announcement no. 2020-04, it was decided at Demant A/S’ ordinary general meeting on 10 March 2020 to reduce the company’s share capital by nominally DKK 919,173.40 divided into 4,595,867 shares of DKK 0.20, corresponding to the company’s holding of treasury shares at 4 February 2020 with the deduction of shares to cover Management's retention programme and the employee share salary arrangement.

The capital reduction was published in the electronic information system of the Danish Business Authority on 12 March 2020. The advertisement period expired without any objections being raised. Consequently, we have notified the Danish Business Authority of the capital reduction. After the capital reduction, the share capital of Demant A/S amounts to nominally DKK 48,138,233.60.

In accordance with Section 32 of the Danish Capital Markets Act, we hereby state that the company’s total share capital and total number of voting rights amount to:

Share capital (nominal):DKK 48,138,233.60
  
Number of voting rights:240,691,168

* * * * * * *

Further information:

Søren Nielsen, President & CEO

Phone

Other contacts:

René Schneider, CFO

Mathias Holten Møller, Head of IR

Christian Lange, IR Officer

Trine Kromann-Mikkelsen, VP Corporate Communication and Relations



Attachment

EN
20/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Demant A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK300.00) - Headwinds set to persist in Q1

We forecast Q1 organic sales growth of just 0.6% YOY, below the full-year guidance, owing to persistent headwinds in wholesale. However, with Managed Care headwinds set to annualise from Q2, better quarters should lie ahead. We expect an unchanged 2025 guidance of 3–7% organic sales growth and DKK4.5bn–4.9bn in EBIT, but we find the lower end most likely. We reiterate our BUY but have cut our target price to DKK300 (320).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch